MedPath
FDA Approval

Deferoxamine mesylate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
ApoPharma USA, Inc.
DUNS: 962810821
Effective Date
March 23, 2018
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Deferoxamine(2 g in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Gland Pharma Limited

918601238

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Gland Pharma Limited

ApoPharma USA, Inc.

Gland Pharma Limited

918601238

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Deferoxamine mesylate

Product Details

NDC Product Code
52609-4504
Application Number
ANDA207384
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
October 7, 2017
Code: V9TKO7EO6KClass: ACTIBQuantity: 2 g in 1 1

Deferoxamine mesylate

Product Details

NDC Product Code
52609-4505
Application Number
ANDA207384
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Effective Date
October 7, 2017
Code: V9TKO7EO6KClass: ACTIBQuantity: 500 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath